Central Trust Company’s GeneDx Holdings WGS Stock Holding History

Central Trust Company’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$481	Hold	7	–	–	﹤0.01%	1532
2026 Q1	$450	Buy	+7	New	+$638	﹤0.01%	1502

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Central Trust Company's WGS Position: Q2 2026 in Review

Central Trust Company held its GeneDx Holdings (WGS) position steady in Q2 2026 at 7 shares worth $481. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Central Trust Company first reported a position in WGS in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Central Trust Company held 7 shares of GeneDx Holdings worth $481 as of Q2 2026.
Central Trust Company left its GeneDx Holdings share count unchanged in Q2 2026.
GeneDx Holdings made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1532 holding.
Central Trust Company first reported a position in GeneDx Holdings in Q1 2026 and has held it in 2 quarters since.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.